



(12) Translation of
European patent specification

(11) NO/EP 3912643 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 47/68 (2017.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office


(45)	Translation Published	2023.01.30
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.10.05
(86)	European Application Nr.	21176545.8
(86)	European Filing Date	2009.12.02
(87)	The European Application's Publication Date	2021.11.24
(30)	Priority	2009.02.13, US, 207890 P
(84)	Designated Contracting States:	AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; SE; SI; SK; SM; TR
(73)	Proprietor	Immunomedics Inc., 300 American Road, Morris Plains, NJ 07950, USA
(72)	Inventor	GOVINDAN, Serengulam, Morris Plains, 07950, USA MOON, Sung-Ju, Morris Plains, 07950, USA GOLDENBERG, David M, Morris Plains, 07950, USA
(74)	Agent or Attorney	AWA NORWAY AS, Hoffsvæien 1A, 0275 OSLO, Norge

(54)	Title	IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE
(56)	References Cited:	WO-A2-2008/088658 US-A1- 2008 166 363 WO-A2-2007/112193 WO-A1-2004/054622 SUNG-JU MOON ET AL: "Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 21, 22 October 2008 (2008-10-22), pages 6916-6926, XP055044282, ISSN: 0022-2623, DOI: 10.1021/jm800719t T. M. CARDILLO ET AL: "Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys", CLINICAL CANCER RESEARCH, vol. 17, no. 10, 3 March 2011 (2011-03-03) , pages 3157-3169, XP055398728, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2939

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Konjugat som har strukturformel Mab-CL2A-SN-38, med en struktur representert ved:



5 hvor MAb'et er hRS7.

2. Farmasøytisk sammensetning omfattende et konjugat ifølge krav 1 og en farmasøytisk akseptabel eksipiens.

3. Farmasøytisk sammensetning ifølge krav 2, hvor eksipiensen er sterilt fosfatbufret saltvann.

10 4. Farmasøytisk sammensetning ifølge krav 2 eller 3, for anvendelse ved behandling av kreft.

5. Farmasøytisk sammensetning for anvendelse ifølge krav 4, hvor kreftarten er valgt fra gruppen bestående av hematopoetisk kreft, karsinom, sarkom, melanom eller en glial svulst.

15 6. Farmasøytisk sammensetning for anvendelse ifølge krav 4, hvor kreftarten er valgt fra gruppen bestående av karsinomaer i lunge, mage, urinblære, bryst, eggstokk, livmor og prostata.